You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Her3/ErbB3

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma Trial in Scottsdale,

Not yet recruiting
  • Metastatic Colon Adenocarcinoma
  • +5 more
  • Trastuzumab
  • +2 more
  • Scottsdale, Arizona
  • +2 more
Jan 31, 2023

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +4 more
  • New York, New York
    Memorial Sloane Kettering Cancer Center
Jan 11, 2023

Breast Cancer Trial in Spain (U3 1402)

Recruiting
  • Breast Cancer
  • U3 1402
  • Badalona, Barcelona, Spain
  • +9 more
Apr 1, 2022

Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +4 more
  • Necitumumab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Tumor in the Brain Trial in Duarte

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Copper Cu 64-DOTA-Trastuzumab
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Nov 22, 2022

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Los Angeles, California
  • +4 more
Jul 19, 2022

Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in Bellevue, Grand Island, Omaha (drug, other,

Active, not recruiting
  • Estrogen Receptor Negative
  • +15 more
  • Bellevue, Nebraska
  • +3 more
Nov 30, 2022

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +19 more
  • pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

Malignant Female Reproductive System Tumor, Malignant Solid Tumor, Recurrent Malignant Female Reproductive System Tumor Trial

Not yet recruiting
  • Malignant Female Reproductive System Neoplasm
  • +3 more
  • Biopsy
  • +7 more
  • (no location specified)
Nov 9, 2023

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

Recruiting
  • Anatomic Stage II Breast Cancer AJCC v8
  • +19 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
May 11, 2022

Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7 Trial in United States

Recruiting
  • Breast Adenocarcinoma
  • +7 more
  • Multi-epitope HER2 Peptide Vaccine TPIV100
  • +5 more
  • Scottsdale, Arizona
  • +26 more
Aug 17, 2022

HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 Trial in Norfolk, Omaha (drug,

Active, not recruiting
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Norfolk, Nebraska
  • +2 more
Sep 1, 2021

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer Trial (HER3-DXd)

Available
  • Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
  • (no location specified)
Oct 17, 2023

Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult Trial (Patritumab deruxtecan)

Not yet recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Patritumab deruxtecan
  • (no location specified)
May 9, 2023

Breast Cancer Trial (Patritumab deruxtecan, Chemotherapy, Letrozole)

Recruiting
  • Breast Cancer
  • Patritumab deruxtecan
  • +2 more
  • Barcelona, Spain
    Hospital Clinic de Barcelona
Nov 28, 2022

HER3 Expression in Non-Small Cell Lung Cancer

Recruiting
  • Non-small Cell Lung Cancer
  • Archival tissue specimen and immunohistochemistry staining
  • Miami, Florida
  • +1 more
Mar 14, 2023

Primary Breast Cancer Trial (SPECT)

Not yet recruiting
  • Primary Breast Cancer
  • (no location specified)
Jun 19, 2023

Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)

Not yet recruiting
  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 20, 2023

NSCLC, Pancreatic Cancer, Locally Advanced Solid Tumor Trial in Sydney (HMBD-001, Docetaxel, Nab-paclitaxel)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 16, 2023

HER2-HER3 Dimer in Tumour and Blood Samples From HER2 Positive

Recruiting
  • HER2-positive Breast Cancer
  • Acquisition of blood samples and tumour tissue samples (biopsies)
  • Brighton, United Kingdom
  • +1 more
Nov 9, 2022

Breast Cancer Female Trial in Tomsk ([99mTc]Tc-G3-(G3S)3C)

Enrolling by invitation
  • Breast Cancer Female
  • Tomsk, Russian Federation
    Olga
Jun 19, 2023

HER-2 Positive Advanced Solid Tumors Trial (D3L-001)

Not yet recruiting
  • HER-2 Positive Advanced Solid Tumors
  • D3L-001
  • (no location specified)
Jul 20, 2023

HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

Active, not recruiting
  • HER2-positive Breast Cancer
  • PIK3CA analysis
  • Rome, RM, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023

Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)

Not yet recruiting
  • Esophageal Squamous Carcinoma
  • HER-2 Protein Overexpression
  • (no location specified)
Sep 24, 2023